Table 1.
Summary of studies that reported pulmonary aspergillosis among patients with COVID-19
| Reference | Country | Patients Included (patients with IA/ total of patients) | ICU Patients | MV Patients | IA: diagnosis from ICU admission (days) | Criteria / Definitions used | BAL GM + | Serum GM + |
|---|---|---|---|---|---|---|---|---|
| Alanio | France | 9/27 | 9 | 9 | NA |
CAPA definition (Verweij) AspICU (Blot) Modified AspICU (Schauwvlieghe) EORTC/MSG |
1/7 | 1/9 |
| Bartoletti | Italy | 30/108 | 30 | 30 | 4 (2 to 8) |
CAPA definition (Verweij) AspICU (Blot) Modified AspICU (Schauwvlieghe) |
30/30 | 1/30 |
| Borman | United Kingdom | 61 | 61 | 61 | NA | NA | 5/61 | |
| Dupont | France | 19/106 (17,9%) | 19 | 18 | 10 (4 to 23) | AspICU (Blot) | 5/9 tested | NA |
| Falces-Romero | Spain | 10 | 7 | 7 | NA |
AspICU (Blot) EORTC/MSG |
2/2 tested | 1/2 tested |
| Flikweert | Netherlands | 7 | 7 | 7 | 19,5 (1 to 24) | custom (symptoms and GM + on BAL/serum OR positive BAL cultures) | 6/7 (GM + on fluids, distinction between BAL or Serum NA) | NA |
| Gangneux | France | 7/45 | NA | 7 | NA |
CAPA definition (Verweij) AspICU (Blot) Modified AspICU (Schauwvlieghe) |
NA | 2/7 |
| Helleberg | Denmark | 2/8 | 2 | 2 | 5 and 1 days | NA | 1/1 tested | 1/2 |
| Koehler | Germany | 5/19 | 5 | 5 | NA |
CAPA definition (Verweij) AspICU (Blot) Modified AspICU (Schauwvlieghe) |
3/3 tested | 2/5 |
| Lamoth | Switzerland | 3/80 | NA | 3 | 7 (3 to 8) |
CAPA definition (Verweij) AspICU (Blot) Modified AspICU (Schauwvlieghe) EORTC/MSG |
NA | 1/3 |
| Marr | USA / Spain | 20 | 20 | 20 | 9,5 (-1 to 24) | custom (positive respiratoy fluids cultures OR GM + on serum/BAL or BDG serum) | 0/1 tested | 4/16 tested |
| Mitaka | USA | 4/7 | NA | 4 | 6,8 (1 to 14) | AspICU (Blot) | NA | 1/3 tested |
| Nasir | Pakistan | 5/23 | 5 | 5 | 8 | custom (clinical parameters, radiological findings and mycological data) | NA | 0/9 tested |
| Rothe | Germany | 2/140 | NA | NA | NA | NA | NA | NA |
| Rutsaert | Belgium | 7/34 | 7 | 7 | 8 (5 to 13) |
CAPA definition (Verweij) AspICU (Blot) Modified AspICU (Schauwvlieghe) EORTC/MSG |
5/6 | 1/6 |
| Van Biesen | Netherlands | 9/42 | 9 | 9 | 3 (1 to 19) | AspICU (Blot) | 9 tested | NA |
| Van Arkel | Netherlands | 6/31 | 6 | 6 | 5 (3 to 14) |
CAPA definition (Verweij) AspICU (Blot) Modified AspICU (Schauwvlieghe) |
2/3 tested | 0/3 tested |
| Wang | China | 8/104 | 8 | 4 | 19 | custom (positive BAL or sputum cultures) | NA | NA |
| White | United Kingdom | 25/135 | NA | 25 | NA | 1,2 + modified IAPA guidelines to accepted NBL GM-EIA positivity in place of testing BAL | NA | 1/2 tested |
| Ichai* | France | 6/26 | 6 | 6 | NC | NC | NC | NC |
| Zuo* | China | 6/30 | 6 | 6 | NC | NC | NC | NC |
| Overall | 239 patients |
median 8 days from ICU admission (median 6,8 days of MV) |
60/133 tested | 16/97 tested |
BAL broncho-alveolar lavage, EIA enzyme immunoassays, GM galactomannan, GMI galactomannan index, IA invasive aspergillosis, ICU intensive care unit, MV mechanical ventilation, NA not applicable, NC not classifiable, NBL non-directed bronchial lavage, SV spontaneous ventilation
GM + if GMI on BAL > 1,0 or serum > 0,5
*article was not used in "Results" but only in "Discussion" modified from [13]